News & Media

SK life science

Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company





General business

Strategic alliance and partnership opportunities

Media inquiries and PR

Grant and investigator initiated proposals

Sponsorship requests

Medical information inquiries or report adverse events

SK life science at a glance

  • Headquarters location

    PARAMUS, NJ

  • R&D Begins

    1993

  • Parent Company

    SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group

  • Number of employees

    200+ EMPLOYEES

  • Disease Category Focus

    CNS

  • Pipeline

    8 compounds under clinical development

Newsroom

SK Biopharmaceuticals Wins Export Award for Cenobamate

Full release

Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals’ Seizure Detection Wearable Device at AES 2022

Full release

SK life science Presents Latest Data on XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AES 2022 Annual Meeting

Full release

SK Biopharmaceuticals Names Donghoon Lee, Head of Bio Investment Center of SK Inc., as New CEO

Full release

SK life science To Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Epilepsy Society 2022 Annual Meeting

Full release

SK Biopharmaceuticals Named CES 2023 Innovation Awards Honoree

Full release

SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969

Full release

Expert Consensus Opinions Published in Neurology and Therapy Discuss Adjustment of Anti-Seizure Medication Dosing for Optimal Care

Full release

New Drug Filing for Cenobamate Accepted for Review in Canada and Israel

Full release

SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America

Full release